Type‐I protein arginine methyltransferase inhibition primes anti‐programmed cell death protein 1 immunotherapy in triple‐negative breast cancer
Cancer · 2024
DOI: 10.1002/cncr.35142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Sheyu Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Tianjin University, Tianjin, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Zhejiang Provincial Key R&D Program, National Natural Science Foundation of China, Zhejiang Provincial Natural Science Foundation.
Abstract (Originalsprache)
Background
Immune‐checkpoint blockade (ICB) therapy shows promise for treating aggressive triple‐negative breast cancer (TNBC). However, only some patients benefit from ICB, revealing an urgent need for identifying novel strategies for sensitizing patients to ICB. Previously, the authors demonstrated that type‐I protein arginine methyltransferases (PRMTs) regulated antiviral innate‐immune responses in TNBC by altering RNA splicing. This study aimed to explore the effects of targeting type‐I PRMTs on the tumor microenvironment (TME) and the efficacy of ICB therapy against TNBC.
Methods
Single‐cell transcriptomic analysis was performed to investigate the effects of type‐I PRMT inhibition on the TME, especially T‐cell subsets. Single‐cell T‐cell receptor sequencing was performed to analyze the diversity and dynamics of the T‐cell repertoire. A syngeneic murine model of TNBC was used to evaluate the therapeutic efficacy and immune memory effect of combining a type‐I PRMT inhibitor (MS023) with an anti‐programmed cell death protein 1 (PD‐1) antibody.
Results
Type‐I PRMT inhibition combined with anti–PD‐1 therapy reduced tumor growth. Mechanistically, type‐I PRMT inhibition reshaped the TME. Increased CD8 T‐cell infiltration was verified using flow cytometry. Increased clonotypes and clonal diversity were also observed after MS023 treatment, which contributed to immune memory following combination treatment.
Conclusions
Targeting type‐I PRMT can potentially improve immunotherapeutic efficacies in patients with TNBC. By enhancing the tumor immunogenicity and promoting a more favorable immune microenvironment, this combined approach may enable more patients with TNBC to benefit from immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences, Tianjin University, Tianjin, China.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.
- Department of Medical Oncology (Breast Cancer), Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
ORCID-Profile: Qin Wu
Förderung
- Zhejiang Provincial Key R&D Program
- National Natural Science Foundation of China
- Zhejiang Provincial Natural Science Foundation
Zitieren
APA
Zhang, S., Guo, L., Zhang, Z., Liu, X., Chen, W., Wei, Y., Wang, X., & Wu, Q. (2024). Type‐I protein arginine methyltransferase inhibition primes anti‐programmed cell death protein 1 immunotherapy in triple‐negative breast cancer. Cancer. https://doi.org/10.1002/cncr.35142
Vancouver
Zhang S, Guo L, Zhang Z, Liu X, Chen W, Wei Y, et al. Type‐I protein arginine methyltransferase inhibition primes anti‐programmed cell death protein 1 immunotherapy in triple‐negative breast cancer. Cancer. 2024. doi:10.1002/cncr.35142
BibTeX
@article{Zhang2024,
author = {Zhang, Sheyu and Guo, Lu and Zhang, Ziwen and Liu, Xueying and Chen, Wenjun and Wei, Yong and Wang, Xiaojia and Wu, Qin},
title = {Type‐I protein arginine methyltransferase inhibition primes anti‐programmed cell death protein 1 immunotherapy in triple‐negative breast cancer},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35142}
}
EUVIMED